Pharma: Page

  • Image attribution tooltip
    Adobe Stock
    Image attribution tooltip

    Mallinckrodt plunges after report it's mulling bankruptcy amid opioid trial

    Staring down more than 2,000 opioid lawsuits, the pharma has maxed out its borrowing capacity, raising the possibility of bankruptcy, per Bloomberg. 

    By Andrew Dunn • Sept. 5, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Pharma's reputation among Americans sinks to lowest level in decades: poll

    According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

    By Kristin Jensen • Sept. 4, 2019
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • A photo of AbbVie's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Skyrizi looks ready to soar after strong launch

    Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

    By • Sept. 4, 2019
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis vies for multiple sclerosis dominance with Arzerra trial

    The repurposed cancer drug is aiming at Roche's Ocrevus, but an upcoming full data presentation will tell MS specialists more about its promise.

    By • Aug. 30, 2019
  • Image attribution tooltip
    AbbVie
    Image attribution tooltip

    AbbVie ends Rova-T research after another study setback

    A string of clinical failures derailed AbbVie's ambitions for the cancer drug, which was once predicted to earn billions of dollars in peak sales.

    By Andrew Dunn • Aug. 29, 2019

  • Purdue offering as much as $12 billion to settle opioid claims: report

    The Oxycontin maker would reportedly declare Chapter 11 bankruptcy, becoming a public trust in which profits from drug sales would go to plaintiffs.

    By Ned Pagliarulo • Aug. 28, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biopharma jobs boom in Massachusetts, though challenges still exist

    Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.

    By • Aug. 27, 2019

  • Oklahoma judge orders J&J pay $572M in landmark opioid case

    At issue was J&J's marketing of opioids Duragesic and Nucynta, as well as its supplying of API to other manufacturers via subsidiaries Noramco and Tasmanian Alkaloids.

    By Ned Pagliarulo • Aug. 26, 2019